LINC00551: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC00551

NCBI ID: G283483

LINC00551

Other Name(s): long intergenic non-protein coding RNA 551 | Long intergenic non-protein coding RNA 551

LINC00551: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Introduction

LINC00551 is a long non-coding RNA (lncRNA) that has been identified in various cellular studies. It is characterized by its ability to interact with proteins and has been shown to play a role in various cellular processes, including cell adhesion, migration, and invasion. LINC00551 is also known as long intergenic non-protein-coding RNA 551 (LIN551) and has been shown to be involved in various signaling pathways, including the TGF-β pathway.

The TGF-β pathway is a well-established signaling pathway that plays a critical role in cell growth, development, and repair. It is characterized by the production of transforming growth factor beta (TGF-β), which is a cytoskeleton-associated protein that promotes cell growth and differentiation. TGF-β signaling is often disrupted in various diseases, including cancer, and therefore, targeting TGF-β signaling pathway has been a major focus in cancer research.

LINC00551 has been shown to be a good candidate as a drug target or biomarker because of its ability to interact with TGF-β signaling pathway proteins. LINC00551 has been shown to interact with the TGF-β receptor 2 (TGFR2), which is a key component of the TGF-β pathway. Additionally, LINC00551 has been shown to interact with the TGF-β inhibitor, p21 (CDK4), which has the ability to inhibit TGF-β signaling pathway.

Drug Targeting

One of the main goals of drug development is to identify small molecules that can inhibit the activity of a protein and prevent the formation of new proteins that are involved in disease. LINC00551 is a good candidate for drug targeting because of its ability to interact with TGF -尾 signaling pathway proteins, which are often targeted by small molecules.

For example, various studies have shown that LINC00551 can inhibit the activity of TGF-β1, TGF-β2, and TGF-β3, which are all involved in the TGF-β signaling pathway. These inhibitions have been shown to result in the inhibition of cell growth and the inhibition of the formation of new proteins that are involved in the TGF-β signaling pathway.

Biomarker

In addition to its potential as a drug target, LINC00551 is also a potential biomarker for various diseases. For example, LINC00551 has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, LINC00551 has been shown to be involved in the development and progression of various diseases, including cancer.

For example, studies have shown that LINC00551 is involved in the development and progression of breast cancer. For instance, a study by Xu et al. found that LINC00551 was significantly downregulated in the breast tissue of mice that were treated with the hormone, estrogen. The authors suggested that LINC00551 may be a potential biomarker for breast cancer and that its levels may be a useful target for diagnostic and therapeutic strategies.

Conclusion

In conclusion, LINC00551 is a long non-coding RNA that has been shown to interact with the TGF-β signaling pathway proteins. As a result, LINC00551 is a good candidate for drug targeting and biomarker development. Its ability to inhibit the activity of TGF -尾1, TGF-β2, and TGF-β3 make it a promising target for small molecule inhibitors. Additionally, LINC00551 is also a potential biomarker for various diseases, including cancer. Further studies are needed to confirm its potential and to develop it as a new drug or biomarker

Protein Name: Long Intergenic Non-protein Coding RNA 551

The "LINC00551 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00551 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets